Logo image of TMCI

TREACE MEDICAL CONCEPTS INC (TMCI) Stock Fundamental Analysis

NASDAQ:TMCI - Nasdaq - US89455T1097 - Common Stock - Currency: USD

6.82  -0.72 (-9.55%)

After market: 6.82 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TMCI. TMCI was compared to 190 industry peers in the Health Care Equipment & Supplies industry. TMCI scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TMCI is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

TMCI had negative earnings in the past year.
In the past year TMCI has reported a negative cash flow from operations.
TMCI had negative earnings in each of the past 5 years.
TMCI had a negative operating cash flow in each of the past 5 years.
TMCI Yearly Net Income VS EBIT VS OCF VS FCFTMCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M -50M

1.2 Ratios

TMCI has a Return On Assets (-25.68%) which is in line with its industry peers.
TMCI has a Return On Equity (-49.38%) which is in line with its industry peers.
Industry RankSector Rank
ROA -25.68%
ROE -49.38%
ROIC N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
TMCI Yearly ROA, ROE, ROICTMCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400 -500

1.3 Margins

With an excellent Gross Margin value of 80.37%, TMCI belongs to the best of the industry, outperforming 93.65% of the companies in the same industry.
TMCI's Gross Margin has been stable in the last couple of years.
TMCI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 80.37%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
TMCI Yearly Profit, Operating, Gross MarginsTMCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

4

2. Health

2.1 Basic Checks

TMCI does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, TMCI has more shares outstanding
Compared to 5 years ago, TMCI has more shares outstanding
TMCI has a worse debt/assets ratio than last year.
TMCI Yearly Shares OutstandingTMCI Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 20M 40M 60M
TMCI Yearly Total Debt VS Total AssetsTMCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

TMCI has an Altman-Z score of 2.32. This is not the best score and indicates that TMCI is in the grey zone with still only limited risk for bankruptcy at the moment.
The Altman-Z score of TMCI (2.32) is better than 64.55% of its industry peers.
A Debt/Equity ratio of 0.47 indicates that TMCI is not too dependend on debt financing.
TMCI has a Debt to Equity ratio of 0.47. This is comparable to the rest of the industry: TMCI outperforms 41.80% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Altman-Z 2.32
ROIC/WACCN/A
WACC8.83%
TMCI Yearly LT Debt VS Equity VS FCFTMCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.62 indicates that TMCI has no problem at all paying its short term obligations.
TMCI's Current ratio of 4.62 is fine compared to the rest of the industry. TMCI outperforms 71.96% of its industry peers.
TMCI has a Quick Ratio of 3.50. This indicates that TMCI is financially healthy and has no problem in meeting its short term obligations.
TMCI has a better Quick ratio (3.50) than 66.67% of its industry peers.
Industry RankSector Rank
Current Ratio 4.62
Quick Ratio 3.5
TMCI Yearly Current Assets VS Current LiabilitesTMCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.09% over the past year.
The Revenue has grown by 11.89% in the past year. This is quite good.
TMCI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.66% yearly.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
Revenue 1Y (TTM)11.89%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%2.86%

3.2 Future

The Earnings Per Share is expected to grow by 14.19% on average over the next years. This is quite good.
TMCI is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.54% yearly.
EPS Next Y-0.29%
EPS Next 2Y7.94%
EPS Next 3Y9.64%
EPS Next 5Y14.19%
Revenue Next Year9.5%
Revenue Next 2Y9.78%
Revenue Next 3Y9.41%
Revenue Next 5Y14.54%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
TMCI Yearly Revenue VS EstimatesTMCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M
TMCI Yearly EPS VS EstimatesTMCI Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.2 -0.4 -0.6 -0.8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TMCI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TMCI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TMCI Price Earnings VS Forward Price EarningsTMCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TMCI Per share dataTMCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.94%
EPS Next 3Y9.64%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TMCI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREACE MEDICAL CONCEPTS INC

NASDAQ:TMCI (5/9/2025, 8:24:31 PM)

After market: 6.82 0 (0%)

6.82

-0.72 (-9.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04/amc
Inst Owners60.6%
Inst Owner Change0.31%
Ins Owners24.78%
Ins Owner Change6.49%
Market Cap428.91M
Analysts75.38
Price Target11.14 (63.34%)
Short Float %4.76%
Short Ratio5.69
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)42.18%
Min EPS beat(2)9.78%
Max EPS beat(2)74.58%
EPS beat(4)4
Avg EPS beat(4)22.3%
Min EPS beat(4)1.96%
Max EPS beat(4)74.58%
EPS beat(8)6
Avg EPS beat(8)11.56%
EPS beat(12)9
Avg EPS beat(12)11.31%
EPS beat(16)11
Avg EPS beat(16)-131.96%
Revenue beat(2)2
Avg Revenue beat(2)0.98%
Min Revenue beat(2)0.3%
Max Revenue beat(2)1.65%
Revenue beat(4)4
Avg Revenue beat(4)1.36%
Min Revenue beat(4)0.3%
Max Revenue beat(4)2.12%
Revenue beat(8)7
Avg Revenue beat(8)0.91%
Revenue beat(12)11
Avg Revenue beat(12)3.01%
Revenue beat(16)14
Avg Revenue beat(16)2.71%
PT rev (1m)-5.07%
PT rev (3m)17.89%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-19.62%
EPS NY rev (1m)0%
EPS NY rev (3m)-12.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.96%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.82%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.05
P/FCF N/A
P/OCF N/A
P/B 3.8
P/tB 4.66
EV/EBITDA N/A
EPS(TTM)-0.8
EYN/A
EPS(NY)-0.71
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.59
OCFYN/A
SpS3.33
BVpS1.8
TBVpS1.46
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.68%
ROE -49.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 80.37%
FCFM N/A
ROA(3y)-24.09%
ROA(5y)-19.45%
ROE(3y)-52.01%
ROE(5y)-143.15%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.32%
GM growth 5Y-0.08%
F-Score3
Asset Turnover0.96
Health
Industry RankSector Rank
Debt/Equity 0.47
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 137.7%
Cap/Sales 5.54%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.62
Quick Ratio 3.5
Altman-Z 2.32
F-Score3
WACC8.83%
ROIC/WACCN/A
Cap/Depr(3y)349.5%
Cap/Depr(5y)305.94%
Cap/Sales(3y)7.38%
Cap/Sales(5y)5.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%16.67%
EPS Next Y-0.29%
EPS Next 2Y7.94%
EPS Next 3Y9.64%
EPS Next 5Y14.19%
Revenue 1Y (TTM)11.89%
Revenue growth 3Y30.41%
Revenue growth 5Y39.66%
Sales Q2Q%2.86%
Revenue Next Year9.5%
Revenue Next 2Y9.78%
Revenue Next 3Y9.41%
Revenue Next 5Y14.54%
EBIT growth 1Y-8.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year100.69%
EBIT Next 3Y32.91%
EBIT Next 5Y26.75%
FCF growth 1Y-5.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-7.5%
OCF growth 3YN/A
OCF growth 5YN/A